AstraZeneca Pharmaceuticals LP
NEWS
Privately-held Grunenthal GmbH will pay AstraZeneca $700 million for the prescription medicine rights to acid-reflux medicine Nexium. The deal with AstraZeneca represents the largest investment in Grünenthal company history.
Abdul Rahman bin Mohammed Al Owais, UAE Minister of Health and Prevention, signed a partnership agreement with Leif Johansson, Chairman of leading global pharmaceutical company AstraZeneca, as part of its strategy to enhance the outcomes of national indicators in the field of respiratory diseases and cancer, to achieve the objectives of the National Agenda 2021.
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
French company Innate Pharma and UK-based AstraZeneca have had a research collaboration deal in place since 2015. The two companies announced a new multi-term deal to build on that collaboration.
AstraZeneca and Merck & Co. presented results at the Presidential Symposium at the European Society for Medical Oncology 2018 Congress held in Munich Germany describing its Phase III SOLO-1 trial of Lynparza (olaparib) in ovarian cancer.
The European Society of Medical Oncology was in full swing this weekend as multiple companies showed off mid- and late-stage assets that could change the way some patients are treated for their cancer. This morning, BioSpace takes a look at some of the announcements.
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here’s a roundup of those changes.
The U.S. FDA approved Pfizer’s PARP inhibitor, Talzenna (talazoparib), for patients with a germline BRCA-mutated (gBRCAm), HER2-negative breast cancer. The agency also approved Myriad Genetics’ diagnostic assay to identify the mutation.
Recently, 23andMe partnered with GlaxoSmithKline, causing the Forbes Technology Council to cite eight ways these types of partnerships will affect disease treatments. These types of partnerships aren’t exactly new.
JOBS
IN THE PRESS